MethylGene Announces the Appointment of Dr. Rodney Lappe to Its Board of Directors

Published: Jun 27, 2012

Montreal, Canada. June 27, 2012 – MethylGene Inc. (TSX: MYG) today announced the election of Rodney Lappe, Ph.D., to the Company’s Board of Directors at the Company’s annual meeting of shareholders held earlier today. “Over the past year we have significantly enhanced our management team while adding four industry leaders to our Board,” said Charles Grubsztajn, President and Chief Executive Officer of MethylGene. “Dr. Lappe’s background complements and enhances our Board, and we welcome his guidance as we advance the Company towards significant milestones.”

Dr. Lappe brings 29 years of drug discovery experience in the pharmaceutical and biotech industries to MethylGene. Before joining Tavistock Life Sciences in early 2012, he was Group Sr. Vice President, Pfizer Worldwide Research and Development and Chief Scientific Officer for CovX in San Diego, California. Dr. Lappe was responsible for the advancement of three novel protein bio-conjugates through his work at CovX that are now in clinical testing as well as two additional clinical candidates in late stage preclinical development. Dr. Lappe was also responsible for the continued growth and productivity of Pfizer’s four internal Biotech Units, Rinat, the Center for Integrated Biology and Biotherapeutics and the Oligonucleotide Technology Unit. He served as Co-lead of the integration of Wyeth R&D after the acquisition by Pfizer in 2009. Prior to joining CovX, Dr. Lappe served as Vice President for cardiovascular and metabolic diseases at Pharmacia where he contributed to the registration of Inspra®, a novel aldosterone receptor antagonist. Prior to joining Pharmacia, he held positions of increasing responsibility with Wyeth, Rorer Central Research, CIBA Geigy and Searle Pharmaceuticals. Dr. Lappe received his PhD in Pharmacology from Indiana University and his BA from Blackburn College.

Dr. David Drutz, who has been a board member since 2001, did not stand for re-election. The Company would like to express its appreciation to Dr. Drutz for his guidance and support over the past 11 years.

About MethylGene

MethylGene Inc. (TSX:MYG) is a small molecule drug development company that is advancing two novel therapeutics for cancer and infectious disease in human clinical trials. The Company’s lead product candidates are: MGCD290, an oral antifungal agent targeting the fungal Hos2 enzyme that is currently in Phase II trials for vulvovaginal candidiasis, and MGCD265, an oral Met/VEGF receptor kinase inhibitor that is in Phase I/II clinical trials for solid tumor cancers. MethylGene owns all rights to its lead product candidates, and has partnerships with Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and EnVivo Pharmaceuticals, Inc. for its other pipeline programs.

Investor Relations Contact:

Joseph Walewicz, CFA

Vice President, Business & Corporate DevelopmentMethylGene Inc.Phone: 514-337-3333 ext. 373

Thomas Fechtner

Vice President

The Trout Group LLC

Phone: 646-378-2931

Back to news